It has been reported that innate resistance to anti-PD-1 immunotherapy is related to the genetic aberrations in the CDK4 pathway, including CDK4, CCND1 gain, and CDKN2A loss in patients with advanced melanoma [131]. Here, CDK4 is linked to melanoma.